BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

Horizon raising cash after Tepezza beats sales estimate Shares of Horizon Therapeutics plc (NASDAQ:HZNP) rose 24% Wednesday, adding nearly $2.9 billion to the company’s market cap after a 2Q20 earnings report that showed that sales...
BioCentury | Dec 19, 2019
Financial News

Versant’s Pipeline raises $30M series B for regenerative therapies

Aiming to enter the clinic before year end, Versant-backed Pipeline Therapeutics raised $30 million in a series B led by new investor Sectoral Asset Management. Versant Ventures also participated in the round, along with new...
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

Karuna added about $1.8 billion in market cap Monday after a Phase II trial showed its combo therapy targeting muscarinic receptors led to significantly lower psychosis scores in patients with schizophrenia while avoiding the side...
BioCentury | Nov 18, 2019

Targeting muscarinic acetylcholine receptors to treat anemia

DISEASE CATEGORY: Hematology INDICATION: Anemia Muscarinic acetylcholine receptor antagonists could treat anemia associated with myelodysplastic syndrome (MDS), aging or hemolysis. In mice with MDS, a CHRM4 inhibitor tool compound, a CHRM1 inhibitor tool compound or...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BioCentury | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
BioCentury | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest M1 muscarinic receptor (CHRM1)-based chemogenetic inhibition of the prelimbic paraventricular thalamic nucleus pathway could help treat cocaine addiction. The system for chemogenetically inhibiting the pathway is initiated by bilateral injection...
BioCentury | Oct 26, 2018
Finance

Springing into Cerevel

Bain Capital is following the blueprint for Pfizer Inc. (NYSE:PFE) spinout SpringWorks Therapeutics LLC and applying it on a larger scale to Cerevel Therapeutics LLC, which will develop Pfizer’s discontinued neuroscience pipeline with $350 million...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest antagonizing the muscarinic receptor CHRM1 could help treat white matter injury. In a mouse model of neonatal chronic hypoxia-induced white matter injury, CHRM1 knockout in oligodendrocyte precursor cells increased axon...
Items per page:
1 - 10 of 184